Imugene Limited

Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies. Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths. The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers. This treatment operates by stimulating a broad polyclonal antibody response against HER2/neu receptors, specifically addressing gastric and breast cancers. Currently, HER-Vaxx is undergoing Phase 1b/2 clinical evaluation for its application in gastric cancer. Beyond its lead product, Imugene is also advancing PD1-Vaxx, another cancer vaccine designed to induce the body to generate polyclonal antibodies that block PD-1 signaling. Additionally, they are developing CF33, a potent oncolytic virus constructed from a unique combination of genomic sequences sourced from various vaccinia virus strains. Imugene has forged a research collaboration with Celularity Inc. to integrate its CD19 oncolytic virus technology with Celularity's CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19, for the treatment of solid tumors. Furthermore, the company maintains a strategic partnership with Eureka Therapeutics, Inc. Established in 1986, Imugene Limited is headquartered in Sydney, Australia.